Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure

Summary

Decreased activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease, was recently reported in cardiovascular diseases and in hepatic failure. Chronic heart failure (CHF) is characterised by abnormalities of left ventricular function accompanied by the failure of the liver and dysregulation of endothelial activation. Therefore, the aim of our study was to measure ADAMTS13 activity in CHF, and determine the prognostic value of VWF and ADAMTS13 on major clinical events in CHF.

ADAMTS13 activity (measured by FRETS-VWF73 substrate) was decreased in CHF (n = 152, left ventricular ejection fraction <45%), and it correlated negatively with B-type natriuretic peptide (BNP) NYHA (New York Heart Association) classes, markers of synthetic capacity of the liver and endothelial dysfunction (all p<0.005). Both, high VWF:Ag levels (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.189–1.943), and low ADAMTS13/VWF:Ag ratios (HR 0.70, 95% CI 0.58–0.84) independently and significantly predicted short-term (1 year followup) clinical adverse events in heart failure (HF).

Decreased activity of ADAMTS13 with concomitant high VWF:Ag levels is a significant independent predictor of clinical events in CHF. The levels of the two molecules may integrate the impaired synthetic capacity of the liver and the disturbed endothelial regulation and can therefore be a useful tool to predict clinical events in CHF.

Keywords

Heart failure - ADAMTS13 - von Willebrand factor - endothelial dysfunction - hepatic failure

• References

• 1 Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 2002; 08: 165-172.
• 2 Lip GY, Pearce LA, Chin BS. et al. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart 2005; 91: 759-763.
• 3 Mastroroberto P, Chello M, Perticone F. Elevated circulating levels of von Willebrand factor and D-dimer in patients with heart failure and mechanical prosthesis. Scand J Thorac Cardiovasc Surg 1996; 30: 77-81.
• 4 Chong AY, Blann AD, Patel J. et al. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004; 110: 1794-1798.
• 5 Chong AY, Freestone B, Patel J. et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006; 97: 671-675.
• 6 Chin BS, Conway DS, Chung NA. et al. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis 2003; 14: 515-521.
• 7 Arya M, Anvari B, Romo GM. et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib- IX complex: studies using optical tweezers. Blood 2002; 99: 3971-3977.
• 8 Arya M, Lopez JA, Romo GM. et al. Measurement of the binding forces between von Willebrand factor and variants of platelet glycoprotein Ibalpha using optical tweezers. Lasers Surg Med 2002; 30: 306-312.
• 9 Feys HB, Canciani MT, Peyvandi F. et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-540.
• 10 Besbas N, Karpman D, Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-431.
• 11 Soejima K, Mimura N, Hirashima M. et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem 2001; 130: 475-480.
• 12 Uemura M, Tatsumi K, Matsumoto M. et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
• 13 Mannucci PM, Canciani MT, Forza I. et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
• 14 Uemura M, Matsuyama T, Ishikawa M. et al. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2005; 29 (Suppl. 12) 264S-271S.
• 15 Matsuyama T, Uemura M, Ishikawa M. et al. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2007; 31 (Suppl. 01) S27-35.
• 16 Liu L, Choi H, Bernardo A. et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 03: 2536-2544.
• 17 Turner N, Nolasco L, Tao Z. et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 04: 1396-1404.
• 18 Manea M, Kristoffersson A, Schneppenheim R. et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007; 138: 651-662.
• 19 Gerritsen HE, Turecek PL, Schwarz HP. et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-1389.
• 20 Molvarec A, Rigo Jr. J, Boze T. et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009; 101: 305-311.
• 21 Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28: 1356-1358.
• 22 Papassotiriou J, Morgenthaler NG, Struck J. et al. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 2006; 52: 1144-1151.
• 23 Akashi YJ, Springer J, Anker SD. Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr Heart Fail Rep 2005; 02: 198-203.
• 24 Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 2004; 126: 213-218.
• 25 Bernardo A, Ball C, Nolasco L. et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-106.
• 26 Bockmeyer CL, Claus RA, Budde U. et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93: 137-140.
• 27 Martin K, Borgel D, Lerolle N. et al. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35: 2375-2382.
• 28 Ono T, Mimuro J, Madoiwa S. et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.
• 29 Bongers TN, de Maat MP, van Goor ML. et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37: 2672-2677.
• 30 Matsukawa M, Kaikita K, Soejima K. et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007; 100: 758-763.
• 31 Crawley JT, Lane DA, Woodward M. et al. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008; 06: 583-588.
• 32 Caprioli J, Castelletti F, Bucchioni S. et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12: 3385-3395.
• 33 Sosin MD, Bhatia G, Davis RC, et aö. Congestive heart failure and Virchow’s triad: a neglected association. Wien Med Wochenschr 2003; 153: 411-416.
• 34 Bowker TJ, Wood DA, Davies MJ. Sudden unexpected cardiac death: methods and results of a national pilot survey. Int J Cardiol 1995; 52: 241-250.
• 35 Farb A, Tang AL, Burke AP. et al. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 1995; 92: 1701-1709.
• 36 Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited. J Am Coll Cardiol 1999; 33: 1424-1426.
• 37 Gibbs CR, Blann AD, Watson RD. et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746-1751.
• 38 Mahdian R, Rayes J, Girma JP. et al. Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples. Thromb Haemost 2006; 95: 1049-1051.
• 39 Molvarec A, Rigo Jr J, Boze T. et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009; 101: 305-311.
• 40 Plaimauer B, Zimmermann K, Volkel D. et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100: 3626-3632.